Product Description
structurally related TLR7 agonist
Mechanisms of Action: TLR7 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis B, Chronic|Hepatitis A
Phase 1: Healthy Volunteers
Recent News Events
Date |
Type |
Title |
|---|